Vivani Medical, Inc. (VANI)
NASDAQ: VANI · Real-Time Price · USD
1.260
-0.030 (-2.33%)
Nov 4, 2024, 4:00 PM EST - Market closed
Vivani Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
69.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xtant Medical Holdings | 110.94M |
Owlet | 65.64M |
TELA Bio | 64.74M |
Hyperfine | 11.94M |
Monogram Technologies | 365.00K |
Zentek | 25.80K |
VANI News
- 13 days ago - Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024 - Business Wire
- 5 weeks ago - Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia - Business Wire
- 6 weeks ago - Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 - Business Wire
- 2 months ago - Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant - Business Wire
- 2 months ago - Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 2 months ago - Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results - Business Wire
- 4 months ago - Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115 - Business Wire
- 5 months ago - Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant - Business Wire